The cell membrane
folate receptor is a potential molecular target for
tumor-selective
drug delivery. To probe structural requirements for
folate receptor targeting with low molecular weight radiometal chelates, specifically the role of the
amino acid fragment of
folic acid (
pteroylglutamic acid) in mediating targeting selectivity, the
amide-linked conjugate pteroyl-NHCH(2)CH(2)OCH(2)CH(2)OCH(2)CH(2)NH-DTPA was prepared by a three-step procedure from
pteroic acid, 2,2'-(ethylenedioxy)-bis(ethylamine), and t-Bu-protected
DTPA. This conjugate, 1-{2-[2-[(2-(biscarboxymethyl-amino)ethyl)-carboxymethyl-amino]ethyl]-carboxymethyl-amino}-acetylamino-3,6-dioxa-8-pteroylamino-
octane (1), was employed for synthesis of the corresponding (111)In(III)
radiopharmaceutical. Following
intravenous administration to athymic mice, the (111)In complex of 1 was found to selectively localize in
folate receptor-positive human KB
tumor xenografts and to afford prolonged
tumor retention of the (111)In radiolabel (5.4 +/- 0.8, 5.6 +/- 1.1, and 3.6 +/- 0.6% of the injected dose per gram of
tumor at 1, 4, and 24 h, respectively). The observed
tumor localization was effectively blocked by co-administration of
folic acid with the (111)In-1 complex, consistent with a
folate receptor-mediated targeting process. In control studies,
tumor targeting with this
pteroic acid conjugate appears as effective as that seen using (111)In-DTPA-folate, a
radiopharmaceutical that has progressed to clinical trials for detection of
folate receptor-expressing gynecological
tumors.